Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

A panel discussion at the Global Life Science Partnering and Investor Conference discusses various strategies and trends in ...

ECIM 2025 saw a heated discussion on whether anticoagulation in DVT should be treated like a chronic condition, as new ...

Insilico Medicine has raised $110 million in Series E funding for its artificial intelligence-powered drug discovery ...

Insilico Medicine Inc. is considering an initial public offering after securing funding at a valuation of more than $1 ...

pharmacy and medicine. There are now over 110,000 employees working for Sanofi in over 100 countries, which includes the United Kingdom, United States, Canada, Germany, Russia, Spain, Australia ...

Insilico Medicine('Insilico'), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced today that it has successfully secured a $110 million Series E ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...